Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Treatment Characteristics and Outcomes of Patients With C... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies
0
Authors
Hande Tuncer
34 more
Hande Tuncer
•
Nilanjan Ghosh
32 more
•
Mazyar Shadman
Published
September 1, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Abstract
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Clinical Lymphoma Myeloma & Leukemia
Topics
Medicine
Cancer Oncology
Internal Medicine
Genetics
Receptor
Show all topics
DOI
10.1016/s2152-2650(24)00591-3
